Boardroom Alpha
Start trial
Boardroom Alpha
RGEN · Current Report (Form 8-K) · Filed May 15, 2026

Repligen Corp — Current Report (Form 8-K)

Form
8-K
Filed
May 15, 2026
Period
May 14, 2026
Ticker
RGEN
Accession
0001193125-26-225380
Repligen Corp on Boardroom AlphaView on SEC EDGAR
Boardroom Alpha · Filing insights

All nine director nominees elected; EY was ratified as independent auditor; advisory executive compensation approved.

About Repligen Corp
Market cap
$6.8B
1Y TSR
−7.0%
3Y TSR
−9.6%
Board grade
C-
Sector
Healthcare
CEO
Olivier Loeillot
Last annual meeting: May 14, 2026 · View full Repligen Corp profile →
8-K

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 14, 2026

 

 

REPLIGEN CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-14656

04-2729386

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

41 Seyon Street

 

Waltham, Massachusetts

 

02453

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (781) 250-0111

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

RGEN

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

On May 14, 2026, Repligen Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). As of March 16, 2026, the record date for the 2026 Annual Meeting, 56,399,274 shares of the Company’s common stock were issued and outstanding, of which 54,022,359 shares were represented, in person or by proxy, at the 2026 Annual Meeting, constituting a quorum. At the 2026 Annual Meeting, the Company’s stockholders voted on the following proposals, which are described in detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 2, 2026:

i.
to elect the nine (9) director nominees identified in the Proxy Statement to the Company’s Board of Directors;
ii.
to consider and ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026; and
iii.
to consider and act upon a non-binding, advisory vote to approve the compensation of the Company’s named executive officers.

Each of the director nominees in proposal 1 were duly elected by, and each of proposals 2 and 3 were approved by, the Company’s stockholders at the 2026 Annual Meeting. The following voting results are final:

Proposal 1 - Election of the Board of Directors

Nominee

 

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

Olivier Loeillot

 

 

51,750,665

 

 

 

116,198

 

 

 

31,383

 

 

 

2,124,113

 

Martin Madaus, D.V.M., Ph.D.

 

 

51,091,036

 

 

 

775,295

 

 

 

31,915

 

 

 

2,124,113

 

Karen A. Dawes

 

 

42,726,647

 

 

 

9,132,553

 

 

 

39,046

 

 

 

2,124,113

 

Nicolas M. Barthelemy

 

 

51,526,602

 

 

 

339,481

 

 

 

32,163

 

 

 

2,124,113

 

Carrie Eglinton Manner

 

 

41,987,697

 

 

 

9,871,020

 

 

 

39,529

 

 

 

2,124,113

 

Konstantin Konstantinov, Ph.D.

 

 

51,137,462

 

 

 

728,874

 

 

 

31,910

 

 

 

2,124,113

 

Rohin Mhatre, Ph.D.

 

 

51,649,920

 

 

 

215,384

 

 

 

32,942

 

 

 

2,124,113

 

Glenn P. Muir

 

 

38,592,456

 

 

 

13,265,484

 

 

 

40,306

 

 

 

2,124,113

 

Margaret A. Pax

 

 

51,011,846

 

 

 

849,103

 

 

 

37,297

 

 

 

2,124,113

 

Proposal 2 - Ratification of the Appointment of Independent Registered Public Accounting Firm

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

 

53,092,462

 

 

 

900,084

 

 

 

29,813

 

 

 

—

 

Proposal 3 - Advisory Vote on Compensation of the Named Executive Officers

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

 

50,333,558

 

 

 

1,513,515

 

 

 

51,173

 

 

 

2,124,113

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

REPLIGEN CORPORATION

 

 

 

 

Date:

May 15, 2026

By:

/s/ Olivier Loeillot

 

 

 

Olivier Loeillot

 

 

 

President and Chief Executive Officer

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

See Filings IntelligenceSchedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Repligen Corp (RGEN)

Continue researching
Reference

Frequently asked questions

When did Repligen Corp file this 8-K?
Repligen Corp (RGEN) filed this Current Report (Form 8-K) with the SEC on May 15, 2026. The accession number assigned by EDGAR is 0001193125-26-225380.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
All nine director nominees elected; EY was ratified as independent auditor; advisory executive compensation approved. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Repligen Corp's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Repligen Corp has filed under CIK 730272, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer